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Flipping the Myc switch
When certain cells differentiate, Myc in Myc-Max heterodimers is
replaced by Mad or Mxi, generating heterodimers that suppress
transcription by interacting with the repressor Sin3.
Members of the myc family of proto-oncogenes are
deregulated in a variety of human malignancies. Ampli-
fication of N-myc, L-myc and c-myc genes is found in
several types of human cancer. Furthermore, chromoso-
mal translocations involving c-myc and point mutations
in the c-myc coding region frequently occur in Burkitt's
lymphoma. Some insight into the function of Myc pro-
teins has come from the identification of two motifs
in their carboxyl termini that are also present in a num-
ber of transcription factors: the basic-helix-loop-helix
(bHLH) and leucine zipper (Zip) motifs (Fig. 1). These
motifs are required for sequence-specific DNA binding
and protein dimerization. In addition, the amino termi-
nus of Myc proteins includes a strong and highly con-
served transactivation domain (Myc box 1), and a second
conserved motif (Myc box 2) that appears to be involved
in transcriptional repression [1]. Importantly, both Myc
box 1 and Myc box 2 are required for cell transforma-
tion. These observations indicate that Myc proteins are
transcription factors that exert their effect on cellular
physiology by activation of some genes and suppression
of others.
The activity of c-myc is regulated at several levels. First,
when quiescent cells are stimulated by growth factors,
c-myc transcription is rapidly and transiently induced. In
exponentially growing cells, c-myc mRNA and protein
levels are invariant. However, they decline following
the induction of differentiation. In addition to regula-
tion at the level of transcription, both transactivation
and DNA binding by c-Myc are highly regulated. The
c-Myc transactivation domain is modulated in two dif-
ferent ways. Phosphorylation of residues Thr58 and
Ser62 within the Myc transactivation domain (Fig. 1)
occurs in a highly cell-cycle-regulated fashion [2]. In
Burkitt's lymphoma, residue Thr58 is often mutated,
resulting in enhanced c-Myc transforming activity. This
suggests that phosphorylation at Thr58 negatively regu-
lates c-Myc. In contrast, mutation of Ser62 severely
reduces the transforming activity of c-Myc, suggesting
that phosphorylation of this residue positively regulates
c-Myc [3]. Myc is also regulated by the retinoblastoma-
related protein p107, which binds to the transactivation
domain of c-Myc and greatly inhibits its ability to
activate transcription [4,5].
A third level of Myc regulation comes from its ability to
form heterodimers with other DNA-binding proteins.
Sequence-specific DNA binding by Myc proteins
requires dimerization to a second bHLH-Zip protein,
known as Max [6] (Fig. 1). Myc-Max heterodimers can
activate the expression of reporter genes that carry a
CACGTG consensus Myc-Max DNA-binding site [7].
Max can also form homodimers that bind the same DNA
site. As Max lacks a transactivation domain, Max homo-
dimers do not activate transcription, but rather repress
CACGTG-containing promoters by competition with
Myc-Max heterodimers and other transcription factors
(such as USF and TFE3) for binding to the same site.
High levels of Max expression, generating excess Max-
Max homodimers, can thus suppress c-Myc transacti-
vation. Under physiological conditions, Myc-Max het-
erodimers are favored over Max-Max homodimers.
Induction of c-Myc synthesis is therefore thought to result
in a shift from Max-Max homodimers to Myc-Max
heterodimers.
Fig. 1. Schematic representation of the
factors that can bind the CACGTG Myc
DNA-binding site. See text for details.
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Fig. 2. Possible complexes and activities
of complexes on the CACGTG Myc-
binding site. Activation of Myc target
genes occurs when a Myc-Max het-
erodimer binds to the CACGTG site in a
Myc-responsive promoter. c-Myc trans-
activation can be modulated by amino-
terminal phosphorylation or by binding
of the retinoblastoma-related protein
p107 to the c-Myc transactivation
domain. Max-Max and Mxi-WR-Max
dimers compete with Myc-Max het-
erodimers for binding to the same site,
leading to weak suppression of the
CACGTG element. Strong suppression
on this element is seen when the Sin3
transcriptional repressor is recruited to
the site by ternary complex formation
with either Mxi-SR or Mad proteins.
Two new players in this game of musical chairs around the
CACGTG motif have recently been identified [8,9]. Mad
and Mxi are related bHLH-Zip proteins that both form
heterodimers with Max, but not with other bHLH-Zip
proteins. Both Mad-Max and Mxi-Max heterodimers
bind the Myc-Max consensus site [8,9]. Like Myc-Max
heterodimers, Mad-Max heterodimers are favored over
Max-Max homodimers [9]. Because Mad lacks a transac-
tivation domain, it cooperates with Max to repress tran-
scription of a Myc-site-containing reporter plasmid [9].
Consistent with this antagonistic effect of Mxi and Mad
on c-Myc, both Mxi and Mad have been found to sup-
press cotransformation by c-myc plus ras of rat primary
embryo fibroblasts.
When myeloid cells are induced to differentiate, dramatic
changes are observed in the protein complexes that bind
to the c-Myc DNA-binding site. The mRNA and pro-
tein levels of the central character, Max, are invariant
during cell division and differentiation [10]. In contrast,
c-Myc levels decline following the induction of mono-
cytic differentiation, whereas both Mxi and Mad levels
rise sharply [8,10]. These changes in protein expression
levels cause a reshuffle in the protein partners that bind to
Max. In undifferentiated U937 myeloid leukemia cells,
only Myc-Max heterodimers are found. Within 2 hours
following induction of monocytic differentiation, Mad is
first detected in complexes with Max, and, after 48
hours, only Mad-Max heterodimers remain in fully dif-
ferentiated U937 cells [10]. These data indicate that
dynamic changes occur on the Myc-recognition site dur-
ing monocytic differentiation. Whether the change from
Myc-Max to Mad-Max heterodimers is sufficient, alone,
to induce differentiation remains to be investigated.
Two recent papers shed further light on the significance
of this shift from Myc-Max to Mad-Max or Mxi-Max
heterodimers [11,12]. Using yeast two-hybrid interaction
screening - in which proteins that potentially interact
are identified by their ability to bring DNA-binding and
transcriptional activation domains together on the pro-
moter of a reporter gene - the groups of Eisenman [11]
and DePinho [12] isolated proteins that interact with
Mad. Two of these are related mammalian homologs of
the yeast transcriptional repressor Sin3, named mSin3A
and mSin3B. A DNA-binding ternary complex of Mad,
Max and Sin3 can be assembled in vitro. Both Sin3
homologs interact with an amino-terminal region of Mad
thought likely to be or-helical in structure: disruption of
this domain by insertion of two helix-breaking prolines
leads to loss of mSin3 interaction. Significantly, the ability
of Mad to suppress a promoter containing consensus
Myc-Max binding sites correlates with its ability to bind
mSin3 [11]. These data suggest that, during differen-
tiation, the CACGTG motif switches from being a posi-
tive element to a negative element by recruitment of a
transcriptional repressor to the Myc-Max binding site,
thereby silencing Myc-responsive genes in differentiated
cells (Fig. 2).
The motif that mediates binding of Mad to mSin3 is also
present in the amino terminus of Mxi. Importantly, two
Mxi proteins (Figs 1 and 2) can be generated from a sin-
gle mxi gene by alternative mRNA splicing - one ver-
sion, Mxi-SR, that contains the Sin3-interaction domain,
and a shorter version of the protein, Mxi-WR, that lacks
the Sin3-interaction surface [12]. When the proteins
were compared for their ability to suppress c-myc-plus-
ras-mediated transformation of rat embryo fibroblasts,
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only Mxi-SR had strong transformation-repressing activ-
ity, whereas Mxi-WR only weakly interfered with c-myc-
plus-ras transformation [12]. Thus, by differential splicing
of Mxi pre-mRNA, cells can fine-tune the degree of
Myc DNA binding-site suppression.
This dual regulation - activation and suppression medi-
ated via the same site - is reminiscent of the regulation of
E2F, another transcription factor with growth-promoting
activity. Free E2F promotes S-phase entry by stimulating
the expression of genes involved in cell-cycle progression.
In contrast, a complex between E2F and the retinoblas-
toma protein acts as an active repressor on the same site
[13]. This may indicate that non-proliferating cells need
actively to suppress the expression of growth-stimulatory
genes by recruitment of transcriptional repressors to their
promoters. It will be of interest to see what the effect is of
loss of mSin3 gene function on cell proliferation. It will
probably not be too long before we find out.
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